Chronix Biomedical
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.
Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight
Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.
Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).
Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286
Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.
Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41
Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.
High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer
Chronix Biomedical
The poster presentation will cover results of a study evaluating the Copy Number Instability (CNI) score as a prognostic test in head and neck cancer.
Chronix Biomedical
First study of a liquid biopsy to predict response to immunotherapy...
Chronix Biomedical
Data from pilot studies using Chronix’s CNI test submitted for presentation at a high profile scientific meeting...
Chronix Biomedical
The best way to fight cancer is to diagnose it in its early stage...
